Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2016

Iasonos Alexia, Chapman Paul B, Satagopan Jaya M

Abstract excerpt

An increased interest has been expressed in finding predictive biomarkers that can guide treatment options for both mutation carriers and noncarriers. The statistical assessment of variation in treatment benefit (TB) according to the biomarker carrier status plays an important role in evaluating predictive biomarkers. For time-to-event endpoints, the hazard ratio (HR) for interaction between treatment and a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Mutation
Share to Proportional Hazards Models

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Risk Assessment

Share to Risk Factors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 27141007
DOI: 10.1158/1078-0432.CCR-15-2517
PMCID: PMC4856220

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.PMID 27141007Read ↗

A hierarchical Bayes model for biomarker subset effects in clinical trialsSemantic proximity Read ↗

Statistical and practical considerations for clinical evaluation of predictive biomarkers.Semantic proximity Read ↗

Evaluating predictive biomarkers for a binary outcome with linear versus logistic regression – Practical recommendations for the choice of the modelSemantic proximity Read ↗

Unveiling non-small cell lung cancer treatment effect heterogeneity: a comparative analysis of statistical methods.Semantic proximity Read ↗

A Framework to Predict the Applicability of Gene Signatures for Improving Prognostic PredictionSemantic proximity Read ↗

Predicting Individual Responses in Phase I Oncology Trials Using Routinely Collected Clinical BiomarkersSemantic proximity Read ↗

Integrative analysis of prognosis data on multiple cancer subtypes.Semantic proximity Read ↗

On Bayesian methods of exploring qualitative interactions for targeted treatment.Semantic proximity Read ↗

Continuous Biomarker Assessment by Exhaustive Survival AnalysisSemantic proximity Read ↗

On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curveSemantic proximity Read ↗

Evaluating a new marker for risk prediction: decision analysis to the rescue.Semantic proximity Read ↗

Biomarker classifiers for identifying susceptible subpopulations for treatment decisions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.